Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)
China · Delayed Price · Currency is CNY 10.03
-0.30 (-2.90%)
Sep 11, 2026, 3:04 PM CST
SHE:000403 Revenue
Pacific Shuanglin Bio-pharmacy had revenue of 486.92M CNY in the quarter ending June 30, 2026, a decrease of -20.42%. This brings the company's revenue in the last twelve months to 2.48B, down -1.16% year-over-year. In the year 2025, Pacific Shuanglin Bio-pharmacy had annual revenue of 2.63B, down -0.83%.
Revenue (ttm)
2.48B
Revenue Growth
-1.16%
P/S Ratio
3.91
Revenue / Employee
898.72K
Employees
2,755
Market Cap
9.69B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.63B | -22.08M | -0.83% |
| Dec 31, 2024 | 2.65B | 325.96M | 14.00% |
| Dec 31, 2023 | 2.33B | -76.47M | -3.18% |
| Jan 1, 2023 | 2.41B | 433.45M | 21.98% |
| Jan 1, 2022 | 1.97B | 921.80M | 87.80% |
| Jan 1, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.03B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Nanjing Vazyme Biotech | 1.47B |
| Vcanbio Cell & Gene Engineering Corp., | 1.40B |
| Hualan Biological Vaccine | 1.19B |
| Mabwell (Shanghai) Bioscience | 873.99M |